Table S1.

Effects of PEG-AuNPs on the cell cycle of PANC-1 cells after 24 hours of exposure

Sample	Concentration (M)	G0/G1 phase		S phase		G2/M phase
		Average	SD	Average	SD	Average	SD
NT	0	51.88	0.96	12.27	0.08	31.09	1.46
AuPEG_1-treated cells	1.3×10−5	51.96	0.81	13.13	0.28	28.74	0.70
	1.9×10−5	52.87	0.29	13.43	0.25	28.20	1.14
AuPEG_2-treated cells	1.4×10−6	55.92	0.64	12.13	0.34	27.29	1.15
	2×10−6	54.13	1.74	12.82	0.57	27.98	1.80
AuPEG_3-treated cells	2.5×10−8	45.01	2.21	20.78	0.34	27.35	3.01
	4×10−8	43.80	0.58	20.30	0.31	30.65	0.41
AuPEG_4-treated cells	2.5×10−8	39.99	2.96	19.61	0.34	32.21	1.61
	4×10−8	41.04	0.11	19.66	0.28	33.73	0.80
Cells exposed to free	1.5×10−6	25.58	0.37	23.16	0.56	42.79	0.21
molecular DOX (PT)

Notes: Values for untreated (negative control [NT]) and 1.5 μM doxorubicin-treated (positive control [PT]) controls are also reported for comparison. Data are reported as average (n_replicates=2) ± standard deviation (SD).

Abbreviations: DOX, doxorubicin; PEG-AuNPs, polyethylene glycol-gold nanoparticles; AuPEG, PEG-coated AuNPs.